PF-Atlas › Clinical Trials › NCT06003426

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

BMS-986278 · Phase 3

Registry ID
NCT06003426
Phase
Phase 3
Status
Active, not recruiting
Drug / intervention
BMS-986278
Sponsor
Bristol-Myers Squibb
Start
2023-09-14
Enrollment
1255
Locations
390

About this trial

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

View NCT06003426 on ClinicalTrials.gov →

Explore related

Admilparant / BMS-986278 — Treatment profileAll BMS-986278 trialsAll IPF trials

Related trials

BMS-986278 — NCT05932303BMS-986278 — NCT05985590BMS-986278 — NCT06025578BMS-986278 — NCT03981094
Medical disclaimer. This page summarizes public trial data for NCT06003426 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.